61 terminated. 61 Phase 2, 9 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 61 | Terminated 61 |
| Phase 3 | 9 | Terminated 9 |
| Phase 1 | 3 | Terminated 3 |
Follow Colitis, Ulcerative: new trials by email Literature Review of Colitis, Ulcerative trials Research Report on Colitis, Ulcerative
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS) balinatunfib, balinatunfib-matching placebo - Colitis Ulcerative, Crohn's Disease | Phase 2 | Terminated | Sanofi | 7 | 2026-05-19 | 2026-10-22 |
| A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis SAR441566, SAR441566 matching Placebo - Colitis Ulcerative | Phase 2 | Terminated | Sanofi | 170 | 2025-03-28 | 2026-10-21 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) Vixarelimab, Placebo - Ulcerative Colitis | Phase 2 | Terminated | Genentech, Inc. | 79 | 2024-05-01 | 2026-02-24 |
| VE202 in Patients With Mild-to-Moderate Ulcerative Colitis VE202, Vancomycin Oral Capsule, VE202 Placebo - Ulcerative Colitis, Colitis, Ulcerative | Phase 2 | Terminated | Vedanta Biosciences, Inc. | 114 | 2023-05-08 | 2025-12-17 |
| Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis Efavaleukin alfa, Placebo - Ulcerative Colitis | Phase 2 | Terminated | Amgen | 25 | 2023-04-28 | 2025-10-15 |
| Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis NX-13 250mg, NX-13 750mg, NX-13 Placebo - Ulcerative Colitis | Phase 2 | Terminated | AbbVie | 81 | 2023-04-24 | 2026-06-15 |
| Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis SPH3127, Placebo - Ulcerative Colitis | Phase 2 | Terminated | Shanghai Pharma Biotherapeutics USA Inc. | 3 | 2022-03-21 | 2025-06-26 |
| Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis Efavaleukin alfa, Placebo - Ulcerative Colitis | Phase 2 | Terminated | Amgen | 221 | 2022-01-31 | 2026-01-13 |
| VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis VTX002, Placebo - Colitis, Ulcerative | Phase 2 | Terminated | Oppilan Pharma Ltd | 213 | 2021-11-30 | 2026-04-30 |
| A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) LY3471851, Placebo - Colitis, Ulcerative | Phase 2 | Terminated | Nektar Therapeutics | 81 | 2021-03-22 | 2023-09-05 |
| Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC) Remestemcel-L, Placebo - Ulcerative Colitis | Phase 1 / Phase 2 | Terminated | The Cleveland Clinic | 7 | 2020-11-10 | 2026-04-16 |
| Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis Rosuvastatin 10mg - Ulcerative Colitis | Phase 2 / Phase 3 | Terminated | Universitaire Ziekenhuizen KU Leuven | 177 | 2020-10-22 | 2025-11-25 |
| A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC) GB004, Placebo - Ulcerative Colitis | Phase 2 | Terminated | GB004, Inc. | 236 | 2020-10-19 | 2023-08-01 |
| TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C - Ulcerative Colitis (UC) | Phase 2 / Phase 3 | Terminated | Theravance Biopharma | 46 | 2020-07-23 | 2022-11-02 |
| Open-label Extension Study of Brazikumab in Ulcerative Colitis Brazikumab Maintenance Dose, Brazikumab Induction Dose - Ulcerative Colitis | Phase 2 | Terminated | AstraZeneca | 57 | 2020-03-03 | 2026-06-23 |
| Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis LYS006, Placebo - Colitis, Ulcerative | Phase 2 | Terminated | Novartis Pharmaceuticals | 23 | 2020-02-03 | 2024-06-20 |
| Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis Tilpisertib, Placebo - Ulcerative Colitis | Phase 2 | Terminated | Gilead Sciences | 19 | 2019-12-20 | 2022-08-24 |
| The Role of Secondary Bile Acids in Intestinal Inflammation ursodiol (ursodeoxycholic acid, UDCA) - Ulcerative Colitis, Pouchitis | Phase 2 / Phase 3 | Terminated | Stanford University | 2 | 2019-08-26 | 2026-03-11 |
| Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis Hemay007, Placebo - Ulcerative Colitis | Phase 2 | Terminated | Tianjin Hemay Pharmaceutical Co., Ltd | 70 | 2019-08-13 | 2024-03-01 |
| Antimicrobial Therapy for Ulcerative Colitis (UC) amoxicillin, metronidazole and doxycycline, amoxicillin and doxycyclin - Ulcerative Colitis | Phase 2 | Terminated | Wolfson Medical Center | 20 | 2019-07-25 | 2022-06-01 |
Showing 20 of 61. Sign in to see all of them.
Inflammatory Bowel Diseases (9) · Colitis (3) · Crohn Disease (3) · Lymphoma, Follicular (3) · Pouchitis (3) · Dysbiosis (1) · Gastrointestinal Diseases (1) · Ileitis (1) · Inflammation (1) · Irritable Bowel Syndrome (1)
Colonic Diseases (61) · Digestive System Diseases (61) · Gastroenteritis (61) · Intestinal Diseases (61) · Gastrointestinal Diseases (60) · Colitis (58) · Inflammatory Bowel Diseases (52) · Enteritis (3) · Hemic and Lymphatic Diseases (3) · Ileal Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3)
visilizumab (3) · AST 120 (1) · Adalimumab (1) · Amoxicillin (1) · Basiliximab (1) · Budesonide (1) · Clotrimazole (1) · Colonoscopy (1) · Cyclosporine (1) · Doxycycline (1) · Enema (1) · Fecal Microbiota Transplantation (1) · Gastroscopy (1) · Hyperbaric Oxygenation (1) · Iron-Dextran Complex (1)
Sanofi (4) · Amgen (2) · AstraZeneca (2) · Facet Biotech (2) · Genentech, Inc. (2) · Gilead Sciences (2) · GlaxoSmithKline (2) · Novartis Pharmaceuticals (2) · Theravance Biopharma (2) · AbbVie (1) · Abbott (1) · Alexion Pharmaceuticals, Inc. (1) · Alimentiv Inc. (1) · AltruBio Inc. (1) · Bayer (1)
United States (42) · Poland (26) · Germany (20) · Italy (20) · Hungary (19) · Canada (18) · Bulgaria (17) · Czechia (17) · Ukraine (17) · France (16) · Israel (13) · Russia (13) · Serbia (13) · South Korea (13) · Australia (12)
Kathy Bohannon (2) · Allard Johane, MD, FRCPC (1) · Amy Lightner (1) · Andreas Muehler (1) · Bana Jabri, MD, PhD (1) · Brian Feagan, MD (1) · Corey A Siegel, MD, MS (1)
PMID 20947884, PMID 21453880, PMID 26119226, PMID 31982148, PMID 34474038, PMID 35014040, PMID 37323059, PMID 39791563, PMID 39793589, PMID 41342324, PMID 41684726
2017 (3), 2018 (3), 2019 (2), 2025 (2), 2005 (1), 2014 (1), 2016 (1), 2023 (1)